Researchers at the Center for Genomic Regulation developed a new method to identify new druggable sites on GPCRs, a family of proteins targeted by one in three drugs. This approach enables the creation of detailed functional maps, leading to more precise control of cellular response and reduced unwanted side effects.
The ISSCR Consortium brings together industry, academia, and regulatory experts to establish standards and develop tools for stem cell-based models. Takeda's membership aims to accelerate the adoption of human stem cell-derived models in drug discovery and development.
Researchers at the University of Cincinnati found a potential biomarker for PTSD susceptibility in female animal models, suggesting a link to stress hormone patterns. The study suggests that a simple stress provocation test could serve as a clinical biomarker for PTSD risk and point toward early interventions. The findings raise the po...
A promising biomarker, GHB-pentose, has been discovered to detect GHB in urine for up to three days after intake, providing a longer detection window. The biomarker has also been found in deceased individuals, potentially helping investigators determine if GHB was ingested before death.
Researchers have developed a light-powered chemical reaction to transform 'dead-end' sulfonamide compounds into useful building blocks for future drug discoveries. This method, using photochemical reactions, can revive these compounds, allowing researchers to create new medicines while preserving their existing features.
Researchers developed FIND, a drug discovery platform that uses DNA nanoswitches to select drug candidates based on their effects on protein-protein interactions. The platform identifies molecules that modulate binding interactions between two proteins, introducing unprecedented functionality and efficiency into drug screening.
New research in SLAS Discovery highlights the use of AI, automation, and novel assays to accelerate therapeutic discovery. These technologies are being applied to address infectious disease, oncology, and rare genetic disorders, leading to innovative solutions for human disease treatment.
SLAS Technology journal Volume 41 features research on type 2 diabetes treatment, computational intelligence, and nanofiber engineering. The journal aims to advance life sciences discovery through education, knowledge exchange, and global community building.
Researchers found that sotagliflozin reduces excessive platelet activation, a process that can lead to dangerous blood clots that block flow to the heart and brain. The drug also makes platelets less likely to stick together and form blood clots, potentially lowering the risk of heart attack and stroke.
A University of Oklahoma researcher is using a $1.9 million NIH award to study how the body moves drugs into the liver and how other medications can disrupt that process. The goal is to develop a strategy that better predicts transporter-related drug interactions before patients are harmed.
Researchers at the University of California San Diego have isolated a marine-derived compound that demonstrates significant potency against the parasite that causes primary amoebic meningoencephalitis, a disease with a fatality rate exceeding 97%. The compound, rutamycin B, achieves full potency within just four hours, outpacing curren...
Researchers at KAIST have developed an implantable neural chip that integrates neurotransmitter sensing, light stimulation, and wireless monitoring. The chip was tested in miniature pigs and showed an increase in neurotransmitter signal following drug administration, followed by a gradual return to baseline.
Researchers at HZI and HIPS discovered a new class of compounds with possible relevance for cancer research from myxobacteria. The compounds, called myxoglucamides, have an unusual structure and bind to the human protein AKR1C3, which is overproduced in several types of cancer.
Melanie Ott and Alex Marson, directors at Gladstone Institutes, have been elected to the National Academy of Medicine for their pioneering achievements in science and medicine. Their work focuses on understanding viral mechanisms, developing innovative treatments, and repurposing human immune cells to fight disease.
KAIST researchers developed an unmanned synthesis platform combining robots and light to automate the entire process from mixing raw materials to synthesis and analysis. The platform successfully synthesized the N-methyl pyrrole scaffold and demonstrated potential for continuous manufacturing.
A new control theory framework introduces a mathematical framework for understanding aging and guiding the development of therapies. The framework prioritizes maintaining or recovering acceptable physiological function, rather than targeting every molecular feature to a youthful state.
Life science organizations One Nucleus, SLAS, and ELRIG collaborate for London Bio-Innovation Week, facilitating networking and partnering opportunities. The event aims to promote open access, increase accessibility, and highlight cutting-edge research.
Juvmo, a Parkinson's disease drug, has been approved by the FDA and offers a new treatment option for patients, potentially reducing side effects. The drug's unique mechanism of action provides relief from motor symptoms, and its approval marks a significant milestone in the research of UVA Health scientists.
Researchers at Georgia State University discovered two metabolite-inspired compounds, MLY2 and MLY8, with enhanced anti-inflammatory activity in experimental ulcerative colitis. These compounds showed promise for treating the chronic inflammatory disease, offering an underexplored drug discovery opportunity.
Researchers at KAIST have discovered that VEGF-C brings two VEGFR-3 receptors together, leading to clustering and amplification of lymphangiogenic signaling. This process may provide new strategies for treating related diseases such as lymphedema and cancer metastasis.
New research on Acanthamoeba's mitochondrial metabolism could lead to safer, more effective treatments for eye and brain infections. The study's findings suggest that understanding the amoeba's biochemistry could help develop novel drugs targeting unique proteins involved in building cyst walls.
SLAS Discovery highlights innovative screening platforms and AI-driven analytics for treating oncology, infectious disease, and immunology research. The journal focuses on drug discovery sciences with a strong record of scientific rigor and impact, reporting on research that advances life sciences discovery and technology.
Research in SLAS Technology Vol. 40 explores smartphone glucose sensing and RNA-based therapeutics in Crohn's disease. The publication showcases innovative technologies and scientific advancements in life sciences discovery and development.
New York University researchers have trained an AI model to predict stable tautomers in drug-like molecules, addressing a challenge in molecular design. The model, released as an open-source tool, can analyze large molecular libraries and identify correct tautomer assignments.
A new drug, Kamuvudine K-9, has been shown to preserve nerve fibers and halt neurological damage in a mouse model of multiple sclerosis. The drug, derived from HIV drugs, has been found to be more effective than existing treatments in restoring function and reducing inflammation.
A UCF researcher and her team used AI to screen existing FDA-approved drugs for potential treatments of schwannoma tumors in children with Neurofibromatosis type 2. The research identified 10 promising candidates, with the most favorable targets stopping tumor cell growth by impacting different cellular mechanisms.
The webinar aims to connect Asian researchers with SLAS journals, publishing opportunities, and collaboration. SLAS Discovery and SLAS Technology journals are two peer-reviewed, open-access journals publishing innovative research and technologies.
By creating virtual cells from 4D AI models and digital twins, researchers can predict how mitochondria respond to drug treatment, grouping cells that respond similarly together. This technology has the potential to speed up drug discovery and accelerate research for diseases such as cancer, diabetes, and Alzheimer's.
The conference will explore next-generation biologics and immunotherapies, targeted protein modulation, and emerging therapies for oncogenic drivers. Experts will discuss the role of artificial intelligence in accelerating therapeutic development.
Researchers developed a flexible metal–organic framework, APF-40, to analyze large pharmaceutical molecules with complex structures. The framework enables the determination of structures from microgram-scale samples, aiding drug discovery and natural products research.
A study found that CADD522 strengthened bones in post-menopausal mice while reducing body fat and reversing metabolic changes linked to menopause. The treatment also appeared to reverse menopause-related changes in fatty acids and lipid abnormalities.
Researchers at Helmholtz Munich have identified a tumor protein called ADAMTSL4 as a key driver of cancer cachexia, a wasting process that affects muscle and fat tissue. The protein locally activates the TGF-β signaling pathway, triggering a catabolic program that promotes muscle and fat breakdown.
A new high-throughput tool developed by Stanford University scientists can detect small changes in protein levels within cells, enabling faster and more efficient drug discovery. By amplifying these changes, researchers can identify potential therapeutic targets for diseases like cancer, potentially leading to breakthroughs in treatment.
Researchers have created a high-resolution functional map of human immune cells, revealing intricate circuits that govern health and disease. The dataset provides a powerful framework for designing cancer immunotherapies and treating autoimmune conditions, and serves as a foundation for AI models of biology.
Researchers at Purdue University have developed L-32, a quinolone-based inhibitor that targets PTPN22, a negative regulator of the immune system. This compound promotes robust antitumor immunity and has improved potency, selectivity, and cellular efficacy compared to previous derivatives.
The 13th Aging Research and Drug Discovery Meeting (ARDD) 2026 will bring together leading researchers, clinicians, and industry experts to advance aging research and accelerate age-related disease interventions. Aging is proud to support ARDD as a media partner, promoting the event through its digital and social media channels.
Surzen Biotherapeutics aims to develop effective pain relief without severe side effects by targeting opioid receptor pathways differently. The company plans to use peptides to block dimerization, reducing tolerance and improving efficacy.
Researchers developed a new molecular editing strategy that relocates the nitrogen atom within the pyridine ring, creating positional isomers. This approach preserves substituents while altering properties such as solubility and interactions with biological targets.
Researchers from the University of Rochester's TraCe-bMPS have developed tissue chips that can predict dangerous immune reactions to cancer therapies. The technology, which uses human cells and sensors, has been accepted into the FDA's Innovative Science and Technology Approaches for New Drugs pilot program.
The new integrations provide enterprise AI agents direct access to live, structured research data from Dimensions' 430M+ interconnected records. This allows for AI-assisted analytics across one of the world's most comprehensive linked views of global research activity.
Researchers have found a new compound that promotes joint health and reduces inflammation-related genes in a model of osteoarthritis. The drug, M04, has shown promise as an innovative OA therapy by slowing down the disease process, giving people more years of pain-free living.
Researchers created nearly 700 new cancer models derived from patient tumors to aid in drug development. The models, representing 25 types of cancer, are now available for global use, providing a resource for identifying new drug targets and testing potential treatments.
Scientists at Gladstone Institutes have developed a regenerative treatment using stem cell-derived spinal interneurons to repair damaged neural networks in rats. The new cells not only survived and formed connections with the animals' own neural circuits but also improved breathing-related motor function after transplantation.
A study at USC discovers a common genetic variant in Indigenous American populations that silences the microprotein MENTSH, restoring it improves insulin signaling and blocks diet-induced weight gain. MENTSH-based therapies could offer a precision-medicine approach to Type 2 diabetes.
Revolver Therapeutics, a spin-out company from the University of Bath, has won the Health category of the Royal Society of Chemistry's Emerging Technologies Competition with its proprietary discovery platform. The platform generates and tests millions of constrained peptide drug candidates directly inside living cells, selecting for mo...
Researchers found that even losing one copy of the TBX5 gene can drastically derail heart development due to DNA misfolding. The study reveals a new origin for genetic disease, suggesting that small drops in protein levels can scramble the 3D structure of DNA.
A review study reveals diverse metabolite families containing atypical atoms, including fluorine, selenium, arsenic, and boron, with distinct biological functions and properties. These elements shape natural products with structural and functional versatility, paving ways toward sustainable biotechnologies.
Researchers have identified a widespread source of error in a popular genome study method and created a machine-learning tool to correct it. PATTY uses machine learning to reduce artifacts while preserving real signals in noisy data, giving researchers a clearer view of gene activity control.
SLAS Discovery highlights innovative screening platforms accelerating therapeutic discovery for neurodegenerative diseases, including a newly identified link to Alzheimer's progression. The journal showcases novel technologies and approaches to understand and treat human disease, advancing life sciences discovery and technology.
This volume of SLAS Technology highlights novel laboratory technologies, open-source software, and disease-specific tools for advancing life sciences research and development. The journal emphasizes the importance of education, knowledge exchange, and global community building to drive innovation in biomedical research.
Researchers at Texas A&M University have found a way to intervene early in traumatic brain injuries using a natural, gut-derived chemical that prevents post-traumatic epilepsy from taking root. The treatment reduced brain inflammation, improved memory and mood, protected brain cells, made seizures both rarer and harder to trigger.
Deep learning models accelerate drug design, predict chemical interactions, and engineer stable candidates. AI-powered simulations optimize dosimetry, predicting biodistribution and generating patient-specific digital twins for individualized treatment planning.
Researchers developed a human-safe drug that repairs DNA breaks and reduces inflammation in a mouse model of Alzheimer's disease. The approach targets multiple disease-relevant cellular pathways, providing a broader therapeutic strategy than previous approaches focused on individual disease hallmarks.
Scientists at King's College London have developed a human-safe drug that repairs DNA breaks and reduces inflammation in a mouse model of Alzheimer's disease. This approach targets multiple features of the disease simultaneously, providing a broader therapeutic strategy than previous approaches focused on individual disease hallmarks.
Researchers discovered a potential drug developed at Michigan Medicine reverses metabolic dysfunction-associated steatohepatitis (MASH) in animal models by disrupting the disease-driving pathway that links the gut and liver. DT-109 improved gut health, reducing inflammation in livers of nonhuman primates.
A team of researchers has developed a new method for finding effective tuberculosis drugs by leveraging the PAC-MAN technique and artificial intelligence. The approach uses machine learning models to predict which chemical compounds can penetrate the outer membrane of the bacteria, paving the way for more efficient drug discovery.
BetaDescribe, an AI system, converts protein sequences into detailed textual descriptions of their functions and characteristics. The technology helps bridge the gap between characterized and existing proteins in nature, enabling researchers to rapidly generate evidence-based hypotheses regarding unknown proteins.
A USC interdisciplinary team has identified a promising pathway to turn off brain inflammation before it does its damage, increasing the risk of late-onset Alzheimer's. The Norman and Mary Pattiz Foundation funding will support research on novel drug discovery, early detection, and prevention of Alzheimer's disease.
A team from the University of Osaka has created a high-throughput platform to engineer versatile biosensors that can track lipid molecules in living cells. This method, called Cell surface Liposome Binding (CLiB) assay, uses yeast cells and fluorescence readouts to test protein variants' binding to lipids.
Researchers at Texas A&M University develop a laser technique called TRIP to directly measure quantum forces shaping proteins, enabling accurate prediction of how pharmaceutical drugs interact with them. This breakthrough could lead to the design of medicines tailored to specific diseases, revolutionizing precision medicine.